Botulinum toxin is a new drug for the treatment of migraine

Annotation. Migraine is one of the most common and debilitating neurological disorders, significantly affecting patients' quality of life. The introduction of innovative treatment methods, such as the use of botulinum toxin, opens new opportunities for managing chronic forms of migraine. Despite the availability of numerous therapeutic approaches, the need to enhance treatment efficacy and minimize side effects remains relevant. The aim of this article is to summarize existing data on the efficacy, mechanisms of action, and safety of botulinum toxin in migraine treatment. Additionally, the article compares botulinum toxin with traditional therapeutic methods and outlines promising directions for future research. For the analysis, results from scientific studies published in databases such as PubMed, Cochrane Library, and Google Scholar from 2016 to 2023 were used. Particular attention was given to systematic reviews, meta-analyses, randomized clinical trials, and key publications elucidating the mechanisms of action of botulinum toxin. The analysis also included several earlier studies that laid the foundation for investigating this therapeutic approach. The analysis demonstrated that botulinum toxin effectively reduces the frequency and intensity of migraine attacks in patients with chronic migraine. Key mechanisms of action identified include the modification of pain signal transmission through peripheral and central neural pathways. Botulinum toxin has also shown a high safety profile with minimal risk of serious adverse effects in clinical trials. Compared to other treatment methods, botulinum toxin offers advantages in terms of prolonged action and ease of use. The use of botulinum toxin is a promising treatment for chronic migraine, combining high efficacy and safety. Future research should focus on optimizing dosing, improving administration techniques, and defining patient selection criteria to maximize therapeutic effectiveness.